|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.32 HKD | -1.70% |
|
+1.82% | -10.91% |
| 18/06 | Sinopharm Group Co. Ltd. Approves Ordinary Final Dividend for the Year Ended 31 December 2025, Payable on 18 August 2026 | CI |
| 27/04 | Earnings Season, Tehran Proposal Lift Asian Stock Markets | MT |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Operating Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Product Distribution | ||||||||||
Pharmaceutical Distribution | 39TCr | 41TCr | 44TCr | 44TCr | 44TCr | |||||
Total Assets | 25TCr | 26TCr | 27TCr | 28TCr | 28TCr | |||||
CAPEX | -174.52Cr | -145.24Cr | -142.49Cr | -140.9Cr | -109.79Cr | |||||
D&A | 210.94Cr | 219.61Cr | 237.6Cr | 252.12Cr | 232.68Cr | |||||
Operating Income | 1.38TCr | 1.29TCr | 1.32TCr | 1.22TCr | 1.19TCr | |||||
Healthcare Equipment Distribution | ||||||||||
Medical Devices | 11TCr | 12TCr | 13TCr | 12TCr | 12TCr | |||||
Total Assets | 7.05TCr | 8.58TCr | 9.15TCr | 9.66TCr | 9.07TCr | |||||
CAPEX | -59Cr | -67Cr | -69Cr | -69Cr | -53Cr | |||||
D&A | 54Cr | 62Cr | 68Cr | 71Cr | 64Cr | |||||
Operating Income | 447.77Cr | 508.29Cr | 452.5Cr | 265.16Cr | 257.19Cr | |||||
Other Business | 982.1Cr | 1.02TCr | 1.04TCr | 910.65Cr | 885.29Cr | |||||
Total Assets | 1.98TCr | 2.07TCr | 2.4TCr | 2.4TCr | 2.42TCr | |||||
CAPEX | -3.44Cr | -11Cr | -12Cr | -12Cr | -9.17Cr | |||||
D&A | 8.36Cr | 8.96Cr | 9.12Cr | 9.72Cr | 8.65Cr | |||||
Operating Income | 119.52Cr | 178.32Cr | 119Cr | 91Cr | 88Cr | |||||
Drug Stores and Pharmacies | ||||||||||
Retail Pharmacy | 2.91TCr | 3.3TCr | 3.57TCr | 3.6TCr | 3.84TCr | |||||
Total Assets | 1.57TCr | 1.63TCr | 1.79TCr | 1.68TCr | 1.63TCr | |||||
CAPEX | -43Cr | -26Cr | -25Cr | -25Cr | -19Cr | |||||
D&A | 118.49Cr | 125.78Cr | 128.64Cr | 140.52Cr | 123.46Cr | |||||
Operating Income | 61Cr | 82Cr | 114.46Cr | 32Cr | 60Cr | |||||
Eliminations | -1.59TCr | -1.85TCr | -2.08TCr | -2.29TCr | -2.3TCr | |||||
Total Assets | -1.81TCr | -1.91TCr | -2.35TCr | -2.9TCr | -2.67TCr | |||||
Operating Income | -37Cr | -1.61Cr | 13Cr | 13Cr | 10Cr | |||||
Total Assets | 178.71Cr | 197.97Cr | 196.37Cr | 240.84Cr | 284.92Cr |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
People's Republic of China (PRC) | 52TCr | 55TCr | 60TCr | 58TCr | 58TCr | |||||
Total Assets | 34TCr | 36TCr | 38TCr | 39TCr | 39TCr | |||||
Interest Expense | -374.51Cr | -350.93Cr | -294.57Cr | -272.44Cr | -229.32Cr | |||||
Income Tax Expense | 393.84Cr | 421.84Cr | 450.23Cr | 357.73Cr | 396.52Cr | |||||
D&A | 378.27Cr | 400.16Cr | 424.39Cr | 452.93Cr | 406.6Cr | |||||
CAPEX | -223.28Cr | -232.02Cr | -195.96Cr | -147.15Cr | -149.57Cr | |||||
Gross Profit | 4.41TCr | 4.74TCr | 4.85TCr | 4.43TCr | 4.17TCr | |||||
Net Income | 775.86Cr | 852.57Cr | 905.38Cr | 704.97Cr | 715.51Cr | |||||
EBT | 1.7TCr | 1.86TCr | 1.95TCr | 1.4TCr | 1.48TCr | |||||
Operating Income | 1.97TCr | 2.06TCr | 2.02TCr | 1.62TCr | 1.6TCr |
- Stock Market
- Stocks
- 1099 Stock
- Financials Sinopharm Group Co. Ltd.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition